Ignite Creation Date:
2024-05-06 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 12:47 PM
Study NCT ID:
NCT03558165
Status:
COMPLETED
Last Update Posted:
2022-05-17
First Post:
2018-05-07
Brief Title:
Lung Cancer Next Generation Sequencing Using the Oncomine Comprehensive Assay
Sponsor:
University Health Network Toronto
Organization:
University Health Network Toronto
Study Overview
Official Title:
Lung Cancer Next Generation Sequencing Using the Oncomine Comprehensive Cancer Panel
Status:
COMPLETED
Status Verified Date:
2022-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LU-NGS-2
Brief Summary:
Currently publicly funded standard of care testing in Ontario for stage IV lung cancer patients uses individual gene tests to look for mutations in the EGFR and ALK genes This testing broadens treatment options for patients however there are other gene mutations with corresponding targeted treatments that are not routinely tested for This study will evaluate the utility and added value of using a next generation sequencing NGS panel the Oncomine Comprehensive Assay v3 to profile stage IV lung cancer patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None